Sionna Therapeutics (NASDAQ:SION) Stock Price Down 4.2% – Should You Sell?

Sionna Therapeutics, Inc. (NASDAQ:SION) shares dropped 4.2% during trading on Monday . The company traded as low as $13.11 and last traded at $13.11. Approximately 40,547 shares were traded during trading, a decline of 83% from the average daily volume of 232,004 shares. The stock had previously closed at $13.69.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on SION shares. TD Cowen assumed coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a “buy” rating for the company. Guggenheim started coverage on shares of Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a “buy” rating and a $45.00 price target for the company. Finally, Stifel Nicolaus assumed coverage on shares of Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a “buy” rating and a $32.00 price objective on the stock.

Sionna Therapeutics Stock Performance

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($3.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.68) by ($0.70).

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.